Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV
| العنوان: | Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV |
|---|---|
| المؤلفون: | Filipa Aragão, Joaquim Peraire, Juan Berenguer, Pere Domingo, Belén de la Fuente, Sophie Marguet, María José Galindo, María Dolores Merino, Vicente Estrada, Fernando Lozano, Josefina Garcia, Ramón Teira, Esteban Ribera, Nadia Abdulghani, Helena Diaz-Cuervo, Bernardino Roca, Maria Jose Muñoz, Marta Montero, Elisa Martínez, M. Antonia Sepúlveda, Alberto Romero, Nuria Espinosa, Elisabeth Deig, Paloma Geijo |
| المساهمون: | Institut Català de la Salut, [Teira R] Hospital de Sierrallana, Torrelavega, Spain. [Diaz-Cuervo H] Gilead Sciences, Medical Affairs, Stockley Park HEOR, Spain. [Aragão F] Maple Health Group, New York, New York, United States of America. NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisboa, Portugal. [Marguet S] Amaris Consulting, Health Economics and Market Access (HEMA), Levallois-Perret, France. [de la Fuente B] Hospital de Cabueñes, Gijón, Spain. [Muñoz MJ] Hospital de Basurto, Bilbao, Spain. [Ribera E] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | PLoS ONE PLoS ONE, Vol 16, Iss 4, p e0249515 (2021) PLoS One r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Scientia Plos One r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe |
| بيانات النشر: | Public Library of Science, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, DOLUTEGRAVIR, RNA viruses, Male, Viral Diseases, HIV Infections, Pathology and Laboratory Medicine, Toxicology, Biochemistry, chemistry.chemical_compound, 0302 clinical medicine, Medical Conditions, ANTIRETROVIRAL THERAPY, Immunodeficiency Viruses, Nucleic Acids, terapéutica::farmacoterapia::farmacoterapia combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Medicine and Health Sciences, Public and Occupational Health, 030212 general & internal medicine, Prospective Studies, INFECTED PATIENTS, Multidisciplinary, Protease Inhibitor Therapy, Hazard ratio, Therapeutics::Drug Therapy::Drug Therapy, Combination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], HIV diagnosis and management, Standard of Care, Middle Aged, Viral Load, Vaccination and Immunization, AIDS, Drug Combinations, Infectious Diseases, Medical Microbiology, Research Design, Viral Pathogens, Dolutegravir, Cohort, Viruses, Medicine, Reverse Transcriptase Inhibitors, Female, virus::virus ARN::Retroviridae::Lentivirus::Lentivirus de los primates::VIH [ORGANISMOS], Pathogens, Research Article, medicine.medical_specialty, PHASE-3, Clinical Research Design, Anti-HIV Agents, Science, 030106 microbiology, Immunology, Antiretroviral Therapy, Research and Analysis Methods, Microbiology, 03 medical and health sciences, Antiviral Therapy, Internal medicine, Retroviruses, medicine, Humans, Microbial Pathogens, Survival analysis, SUPPRESSION, Retrospective Studies, Toxicity, Proportional hazards model, business.industry, Lentivirus, Organisms, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Biology and Life Sciences, HIV, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Confidence interval, Diagnostic medicine, Discontinuation, Regimen, chemistry, Medicaments - Eficàcia, Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV [ORGANISMS], HIV-1, RNA, Preventive Medicine, Adverse Events, Medicaments - Administració, business, Persones seropositives |
| الوصف: | Teràpia antiretroviral; Diagnòstic i gestió del VIH; Teràpia amb inhibidors de la proteasa Terapia antirretroviral; Diagnóstico y gestión del VIH; Terapia con inhibidores de la proteasa Antiretroviral therapy; HIV diagnosis and management; Protease inhibitor therapy Background Since 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients. Methods A retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNA |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1932-6203 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::881d13bfafe5b7088fea060081bd6fd9Test http://europepmc.org/articles/PMC8031389Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....881d13bfafe5b7088fea060081bd6fd9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|